Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.
Verve Therapeutics, Inc. (Nasdaq: VERV) is a cutting-edge biotechnology company headquartered in Cambridge, Massachusetts. With a mission to protect the world from heart disease, Verve is pioneering a transformative approach in cardiovascular care. The company leverages two major breakthroughs in 21st-century biomedicine—human genetics analysis and gene editing—to create life-changing therapies for coronary heart disease.
Verve Therapeutics is focused on developing single-course gene editing medicines to permanently lower LDL cholesterol and triglyceride levels in adults, thereby reducing the risk of coronary heart disease. Their innovative treatments are designed to be administered once in a lifetime, offering a potential shift from chronic disease management to a one-time cure.
Founded by leading experts in cardiovascular medicine, human genetics, and gene editing, Verve has garnered substantial support from top-tier investors, including GV (formerly Google Ventures), Arch Venture Partners, and others. The company was recognized as a '2020 Best Places to Work' by the Boston Business Journal, highlighting its positive workplace culture and innovative environment.
Verve's flagship programs include VERVE-101, VERVE-102, and VERVE-201, each targeting genes validated for their role in lowering low-density lipoprotein cholesterol (LDL-C). Specifically, VERVE-101 and VERVE-102 aim to permanently deactivate the PCSK9 gene, initially targeting patients with heterozygous familial hypercholesterolemia (HeFH) and eventually expanding to treat patients with atherosclerotic cardiovascular disease (ASCVD) who have not reached LDL-C goals using traditional therapies. Meanwhile, VERVE-201 targets the ANGPTL3 gene, focusing on patients with homozygous familial hypercholesterolemia (HoFH) and refractory hypercholesterolemia.
Recent milestones for Verve Therapeutics include the first human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b clinical trial of VERVE-101. This study demonstrated dose-dependent reductions in disease-causing LDL-C in patients with HeFH. The company is also progressing with the heart-2 phase 1b clinical trial for VERVE-102 and plans to launch a phase 1b trial for VERVE-201 in the latter half of 2024.
In terms of financial performance, Verve maintains a solid cash position, with $624.0 million in cash and marketable securities as of December 31, 2023. This robust financial standing is augmented by strategic partnerships, including a significant collaboration with Eli Lilly, which involved a private placement and potential milestone payments up to $465 million.
Under the leadership of CEO Sekar Kathiresan, M.D., Verve is pushing the boundaries of cardiovascular disease treatment. The company's relentless commitment to scientific excellence and patient care positions it as a potential game-changer in the field of genetic medicine.
Verve Therapeutics, focused on genetic medicines for cardiovascular disease, announced significant updates and anticipated milestones for 2025.
Pipeline Progress: Initial data from the Heart-2 Phase 1b trial for VERVE-102 targeting PCSK9 is expected in Q2 2025. Dosing has progressed to the 0.6 mg/kg cohort. VERVE-301, targeting the LPA gene, has been nominated as a development candidate, with associated milestone payments from Eli Lilly.
Financial Outlook: The company is well-capitalized with a cash runway extending into mid-2027.
Collaborations: Eli Lilly holds an opt-in right for the PCSK9 program and will fund Phase 1 of the LPA program, with Verve eligible for up to $465 million in milestones and royalties.
Upcoming Events: Verve will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.
Verve Therapeutics (VERV), a clinical-stage biotechnology company focused on developing genetic medicines for cardiovascular disease, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Dr. Sekar Kathiresan, the company's co-founder and CEO, will deliver a presentation on Wednesday, January 15, 2025, at 11:15 a.m. PT in San Francisco.
The presentation will be accessible through a live webcast on the investor section of Verve's website at www.vervetx.com. Interested parties can access the archived version of the webcast for 30 days following the presentation.
Verve Therapeutics, a clinical-stage company focused on genetic medicines for cardiovascular disease, has announced new equity awards granted on December 31, 2024. The company issued 5,330 restricted stock units (RSUs) to one new employee under its 2024 Inducement Stock Incentive Plan. This grant complies with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for employment. The RSUs will vest equally over four years, with annual installments beginning January 1, 2025, contingent on the employee's continued service with the company.
Verve Therapeutics, a clinical-stage biotechnology company focused on genetic medicines for cardiovascular disease, has granted 5,330 restricted stock units (RSUs) to a new employee under its 2024 Inducement Stock Incentive Plan. The grant, made on November 29, 2024, complies with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in equal annual installments over four years starting January 1, 2025, contingent on continued employment.
Verve Therapeutics reported progress in its clinical trials and Q3 2024 financial results. Seven participants were dosed in the Heart-2 Phase 1b trial of VERVE-102, with initial data expected in H1 2025. The first participant was dosed in the Pulse-1 Phase 1b trial of VERVE-201. The company reported $539.9M in cash and equivalents, with runway through 2026. Q3 financial results showed collaboration revenue of $6.9M, R&D expenses of $49.9M, and a net loss of $50.1M ($0.59 per share). VERVE-102 has been well-tolerated with no serious adverse events observed.
Verve Therapeutics has granted equity awards to six new employees as inducement for employment. The awards include 47,600 stock options with an exercise price of $5.73 per share and 42,710 restricted stock units (RSUs). The options have a 10-year term, vesting over four years with 25% vesting after one year and the remainder monthly over three years. The RSUs will vest in equal annual installments over four years starting January 1, 2025. These grants were made under the company's 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics, a clinical-stage company developing genetic medicines for cardiovascular disease, has announced the granting of equity awards to five new employees on September 30, 2024. These awards, made under the company's 2024 Inducement Stock Incentive Plan, are in accordance with Nasdaq Listing Rule 5635(c)(4) and serve as an inducement for employment.
The equity awards consist of an aggregate of 33,280 restricted stock units (RSUs). These RSUs will vest in equal annual installments over four years, starting from October 1, 2024, contingent on the employees' continued service with Verve Therapeutics.
Verve Therapeutics, a clinical-stage company focused on developing genetic medicines for cardiovascular disease, has announced the granting of equity awards to two new employees. The awards, issued on August 30, 2024, consist of a total of 12,600 restricted stock units (RSUs). These grants were made under the company's 2024 Inducement Stock Incentive Plan and are in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest in equal annual installments over a four-year period, starting from October 1, 2024, contingent on the employees' continued service with Verve Therapeutics. This move is part of the company's strategy to attract and retain talent in the competitive biotech sector.
Verve Therapeutics, a clinical-stage company developing genetic medicines for cardiovascular disease, reported Q2 2024 financial results and pipeline updates. Key highlights include:
- Heart-2 clinical trial of VERVE-102 enrolling in the U.K., Canada, and Australia
- VERVE-201 Phase 1b trial initiation on track for H2 2024
- Cash position of $575.9 million, runway into late 2026
- Q2 2024 revenue: $6.7 million; net loss: $49.8 million ($0.59 per share)
- R&D expenses: $51.0 million; G&A expenses: $14.5 million
The company plans to provide initial data from the Heart-2 trial and a PCSK9 program update in H1 2025, with Phase 2 trial initiation expected in H2 2025.
Verve Therapeutics, a clinical-stage company developing genetic medicines for cardiovascular disease, has announced the granting of equity awards to five new employees on July 31, 2024. These awards, made under the company's 2024 Inducement Stock Incentive Plan, include:
1. Stock options to purchase 91,200 shares of common stock at $7.00 per share, vesting over four years.
2. 37,300 restricted stock units (RSUs), vesting in equal annual installments over four years.
These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to serve as an inducement for new employees joining the company.
FAQ
What is the current stock price of Verve Therapeutics (VERV)?
What is the market cap of Verve Therapeutics (VERV)?
What is Verve Therapeutics' main focus?
Where is Verve Therapeutics headquartered?
What are the key programs of Verve Therapeutics?
Who are some of Verve Therapeutics' investors?
What recent milestone has Verve Therapeutics achieved?
What is the financial condition of Verve Therapeutics?
What is VERVE-101 designed to do?
Who is the CEO of Verve Therapeutics?
What is the significance of Verve's collaboration with Eli Lilly?
What recognition has Verve Therapeutics received?
